Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma.
Myxofibrosarcoma (MFS) is an aggressive sarcoma that requires novel therapeutic approaches to improve its clinical outcome. Cell lines are a valuable tool for pre-clinical research; however, there is a lack of patient-derived cell lines of MFS available from public cell banks. This study aimed to develop a patient-derived cell line of MFS. A cell line designated NCC-MFS1-C1 was established from the primary tumor tissue of an 82-year-old male patient with MFS. The short tandem repeat pattern of NCC-MFS1-C1 cells was identical to that of the original tumor, but distinct from that of any other cell lines in public cell banks. NCC-MFS1-C1 cells were maintained as a monolayer culture for over 20 passages in 19 months; the cells exhibited spindle-like morphology, continuous growth, and ability for spheroid formation and invasion. Genomic assay showed that NCC-MFS1-C1 cells had gain and loss of genetic loci. Proteomic profiling revealed that the original tumor and the derived NCC-MFS1-C1 cells had similar, but distinct protein expression patterns. Screening of anti-cancer drugs in NCC-MFS1-C1 cells identified five candidate drugs for MFS. In conclusion, we established a novel MFS cell line, NCC-MFS1-C1, which could be used to study tumor development and effects of anti-cancer drugs.